Phase specific health care costs associated with giant cell arteritis in Ontario, Canada
Junek M, Barra L, Kopp A, Felfeli T, Gatley J, Widdifield J. J Rheumatol. 2024; Apr 1 [Epub ahead of print].
Prescription drug plan managers seek "real-world" evidence regarding the safety and effectiveness of drugs and drug coverage policies. University-based pharmacoepidemiologists with access to administrative health data can help meet these information needs and, by collaborating with other health plans, exploit variations in plan policy. Canada, with its universal health insurance, public drug benefit plans, and population-based linked healthcare databases, is an ideal setting for such research. Here we describe our initial experience in collaborating with researchers and drug plan managers in British Columbia and Ontario.
Paterson JM, Laupacis A, Bassett K, Anderson GM; BC-Ontario Pharmacosurveillance for Decision-Making Collaborative. Health Aff. 2006; 25(5):1436-43.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.